INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 46h ago
HOUSE PTR6h ago
SEC 13F6h ago
ROBINHOOD CHAIN6h ago
Corporate insider
BH

Bernstein Harold

President, R&D & CMOCIK 0002050172

EDGAR filingsOpen in network
Disclosed transactions60
Buys / sells0 / 30
Max Insider Score40
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$168K
16.1K sh
Oct 1, 2026Oct 2, 2026
traded Oct 1, 2026
+1dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Maze Therapeutics, Inc.President, R&D & CMO · Dec 31, 2025
0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
—
16.1K sh
Oct 1, 2026
Oct 2, 2026
traded Oct 1, 2026
+1d
SEC FORM 4

Evidence

21
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$435K
16.1K sh
Oct 1, 2026Oct 2, 2026
traded Oct 1, 2026
+1dSEC FORM 4

Evidence

31
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$255K
9,705 sh
Sep 4, 2026Sep 8, 2026
traded Sep 4, 2026
+4dSEC FORM 4

Evidence

29
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$1,521
59 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

29
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$17K
625 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

40
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$133K
5,130 sh
Sep 3, 2026Sep 4, 2026
traded Sep 3, 2026
+1dSEC FORM 4

Evidence

40
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale
SELL$118K
4,481 sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

31
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$426K
16.1K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
20.0K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
16.1K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$168K
16.1K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
20.0K sh
Sep 1, 2026Sep 3, 2026
traded Sep 1, 2026
+2dSEC FORM 4

Evidence

16
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$446K
16.1K sh
Aug 13, 2026Aug 14, 2026
traded Aug 13, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
16.1K sh
Aug 13, 2026Aug 14, 2026
traded Aug 13, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$168K
16.1K sh
Aug 13, 2026Aug 14, 2026
traded Aug 13, 2026
+1dSEC FORM 4

Evidence

21
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$400K
13.4K sh
Jul 1, 2026Jul 2, 2026
traded Jul 1, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
14.6K sh
Jul 1, 2026Jul 2, 2026
traded Jul 1, 2026
+1dSEC FORM 4

Evidence

15
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$36K
1,200 sh
Jul 1, 2026Jul 2, 2026
traded Jul 1, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$152K
14.6K sh
Jul 1, 2026Jul 2, 2026
traded Jul 1, 2026
+1dSEC FORM 4

Evidence

21
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$339K
13.3K sh
Jun 1, 2026Jun 3, 2026
traded Jun 1, 2026
+2dSEC FORM 4

Evidence

15
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$42K
1,600 sh
Jun 1, 2026Jun 3, 2026
traded Jun 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
14.9K sh
Jun 1, 2026Jun 3, 2026
traded Jun 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$155K
14.9K sh
Jun 1, 2026Jun 3, 2026
traded Jun 1, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
15.0K sh
May 14, 2026May 18, 2026
traded May 14, 2026
+4dSEC FORM 4

Evidence

16
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$393K
15.0K sh
May 14, 2026May 18, 2026
traded May 14, 2026
+4dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$156K
15.0K sh
May 14, 2026May 18, 2026
traded May 14, 2026
+4dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$156K
15.0K sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC FORM 4

Evidence

26
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$332K
11.4K sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC FORM 4

Evidence

23
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$101K
3,348 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC FORM 4

Evidence

20
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$9,320
300 sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
15.0K sh
Apr 1, 2026Apr 2, 2026
traded Apr 1, 2026
+1dSEC FORM 4

Evidence

19
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$187K
3,795 sh
Mar 20, 2026Mar 20, 2026
traded Mar 20, 2026
+0dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$156K
15.0K sh
Mar 20, 2026Mar 20, 2026
traded Mar 20, 2026
+0dSEC FORM 4

Evidence

22
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$297K
6,161 sh
Mar 20, 2026Mar 20, 2026
traded Mar 20, 2026
+0dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
15.0K sh
Mar 20, 2026Mar 20, 2026
traded Mar 20, 2026
+0dSEC FORM 4

Evidence

26
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$252K
5,044 sh
Mar 20, 2026Mar 20, 2026
traded Mar 20, 2026
+0dSEC FORM 4

Evidence

10
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$18K
348 sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

19
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.50M
29.7K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$313K
30.0K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
30.0K sh
Mar 10, 2026Mar 12, 2026
traded Mar 10, 2026
+2dSEC FORM 4

Evidence

29
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$275K
5,936 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

11
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$27K
600 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$156K
15.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
15.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

23
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$4,723
100 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

29
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$384K
8,364 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC FORM 4

Evidence

1
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$262K
25.2K sh
Jan 7, 2026Jan 9, 2026
traded Jan 7, 2026
+2dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
25.2K sh
Jan 7, 2026Jan 9, 2026
traded Jan 7, 2026
+2dSEC FORM 4

Evidence

32
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.01M
25.2K sh
Jan 7, 2026Jan 9, 2026
traded Jan 7, 2026
+2dSEC FORM 4

Evidence

23
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$16K
412 sh
Jan 5, 2026Jan 6, 2026
traded Jan 5, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
412 sh
Jan 5, 2026Jan 6, 2026
traded Jan 5, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$46K
4,432 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

26
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$179K
4,432 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$4,293
412 sh
Jan 5, 2026Jan 6, 2026
traded Jan 5, 2026
+1dSEC FORM 4

Evidence

0
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
4,432 sh
Jan 2, 2026Jan 6, 2026
traded Jan 2, 2026
+4dSEC FORM 4

Evidence

5
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$469K
45.0K sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

3
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
45.0K sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

36
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$1.12M
27.8K sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence

33
BH
Bernstein HaroldPresident, R&D & CMO
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$704K
17.2K sh
Dec 29, 2025Dec 31, 2025
traded Dec 29, 2025
+2dSEC FORM 4

Evidence